Tag Archives: Lycera

← Older posts

New Faces, Big Impact: Meet the Finalists For Xconomy’s Newcomer Award

Being a newcomer can mean a few different things: being new to the area (or newly back after being away) or new to an industry. The finalists for Xconomy’s Newcomer Award this year cover these definitions. One is a serial biotech entrepreneur who has now made an impact in multiple cities, most recently Boston. Another […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on New Faces, Big Impact: Meet the Finalists For Xconomy’s Newcomer Award

IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout

Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

Posted in Boston, Boston blog main, Boston top stories, Detroit blog main, Detroit top stories, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout

Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out

The option-to-buy deal, in biotech, is a way to hedge a bet. A big firm will pay a fee for the right to acquire a smaller company later on, with the big bucks coming only if the acquisition is triggered. An option isn’t a guarantee, however; a big company can always pass on a buyout, […]

Posted in Boston, Boston blog main, Boston top stories, Detroit blog main, National blog main, National top stories, New York blog main, New York top stories, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out

Biotech Roundup: CRISPR’s 1st Trial, IPO Insiders, Zika & More

It’s a week for the history books. The United Kingdom voted to leave the European Union last night, triggering worldwide financial fears and, perhaps, a breakup of the U.K. itself. Closer to home, Cleveland (pictured) celebrated LeBron James & the Cavaliers’ historic comeback that brought the city its first sports title in over 50 years. […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech Roundup: CRISPR’s 1st Trial, IPO Insiders, Zika & More

Atlas, Novartis Put $27M Into IFM to Battle Cancer, Autoimmune Diseases

There is no shortage of companies out there trying to tweak our immune systems in one way or another to treat diseases like cancer. Today, IFM Therapeutics, a new startup seeded by Boston firm Atlas Venture, has joined the fray. IFM, a startup in Cambridge, MA, disclosed a $27 million Series A round led by […]

Posted in Boston, Boston blog main, Boston top stories, Detroit blog main, Detroit top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Atlas, Novartis Put $27M Into IFM to Battle Cancer, Autoimmune Diseases

Lycera Secures $29,892,748 Series B Financing

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=34e39712-ee89-4c9e-b14d-b8f09f530ae4 Date 6/22/2015 Company Name Lycera Mailing Address 2800 Plymouth Rd. Ann Arbor, MI 48109 USA Company Description Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that […]

Posted in Detroit, Detroit VentureDeal VC | Tagged , | Comments Off on Lycera Secures $29,892,748 Series B Financing

East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More

New startups. New data. Financings. Acquisitions. Legal tussles. FDA advisory panels. It’s been that kind of week in East Coast biotech. So grab some coffee and let’s roll through this week’s headlines. —This week a new type of cholesterol-lowering drug was in the spotlight, a class of injectable therapies that block the protein known as […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More

Lycera’s End Game? $104M Celgene Deal Could Lead to Buyout

It’s been a big week for Lycera, a biotech firm focused on immunotherapy that spun out of the University of Michigan nearly a decade ago. On Tuesday, the company announced a deal with Celgene, of Cranbury, NJ, that could spell the beginning of the end for the Michigan biotech. Celgene has taken an option to […]

Posted in Detroit, Detroit blog main, Detroit top stories, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on Lycera’s End Game? $104M Celgene Deal Could Lead to Buyout

Lycera Secures $4,000,000 New Financing Round

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=aff47ee7-21cb-4375-908e-0b81bc4160af Date 4/7/2014 Company Name Lycera Mailing Address 2800 Plymouth Rd. Ann Arbor, MI 48109 USA Company Description Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that […]

Posted in Detroit, Detroit VentureDeal VC | Tagged , | Comments Off on Lycera Secures $4,000,000 New Financing Round

Lycera Obtains $5,000,000 New Funding Round

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=35422332-4b50-4b18-8c73-c731e9b5af56 Date 10/22/2013 Company Name Lycera Mailing Address 2800 Plymouth Rd Ann Arbor, MI 48109 Company Description Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target […]

Posted in Detroit, Detroit VentureDeal VC | Tagged , , | Comments Off on Lycera Obtains $5,000,000 New Funding Round← Older posts